Functional CD8+ T cells infiltrate into nonsmall cell lung carcinoma

Cancer Immunology, Immunotherapy

Volumn 56, Issue 5, 2007, Pages 587-600

  Verdegaal, Elizabeth M E ^a   Hoogstraten, Conny ^a   Sandel, Maro H ^a   Kuppen, Peter J K ^a   Brink, Antoinette A T P ^a   Claas, Frans H J ^a   Gorsira, Michael C B ^b   Graadt Van Roggen, J Frans ^b   Osanto, Susanne ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Diaconessenhuis Hospital   (Netherlands)

Author keywords

Cytotoxic T cells; Granzyme B; HLA class I molecules; Infiltrate; Lung cancer

Indexed keywords

GAMMA INTERFERON; GRANZYME B; HLA ANTIGEN CLASS 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CASE REPORT; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CHROMOSOME 6; CONFOCAL LASER MICROSCOPY; CYTOTOXIC T LYMPHOCYTE; HAPLOTYPE; HLA SYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; LUNG NON SMALL CELL CANCER; LYMPHOCYTE FUNCTION; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STROMA CELL; TUMOR IMMUNITY;

CARCINOMA, NON-SMALL-CELL LUNG; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICROSCOPY, CONFOCAL; MIDDLE AGED; T-LYMPHOCYTE SUBSETS;

EID: 33847354724     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-006-0214-y     Document Type: Article

References (47)

1. Ambrosini G, Adida C, Altieri DC (1997) A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917-921
2. Berrieman HK, Ashman JN, Cowen ME, Greenman J, Lind MJ, Cawkwell L (2004) Chromosomal analysis of non-smallcell lung cancer by multicolour fluorescent in situ hybridisation. Br J Cancer 90:900-905
3. Bladergroen BA, Meijer CJ, ten Berge RL, Hack CE, Muris JJ, Dukers DF, Chott A, Kazama Y, Oudejans JJ, van Berkum O, Kummer JA (2002) Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system? Blood 99:232-237
4. Boldrini L, Faviana P, Pistolesi F, Gisfredi S, Di Quirico D, Lucchi M, Mussi A, Angeletti CA, Baldinotti F, Fogli A, Simi P, Basolo F, Fontanini G (2001) Alterations of Fas (APO-1/CD 95) gene and its relationship with p53 in non small cell lung cancer. Oncogene 20:6632-6637
5. Carr NJ (2000) M30 expression demonstrates apoptotic cells, correlates with in situ end-labeling, and is associated with Ki-67 expression in large intestinal neoplasms. Arch Pathol Lab Med 124:1768-1772
6. Deveraux QL, Takahashi R, Salvesen GS, Reed JC (1997) X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388:300-304
7. Eerola AK, Soini Y, Paakko P (2000) A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma. Clin Cancer Res 6:1875-1881
8. Fisher ER, Anderson S, Tan-Chiu E, Fisher B, Eaton L, Wolmark N (2001) Fifteen-year prognostic discriminants for invasive breast carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol-06. Cancer 91:1679-1687
9. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18:89-95
10. Griffioen M, Borghi M, Schrier PI, Osanto S (2001) Detection and quantification of CD8(+) T cells specific for HLA-A* 0201-binding melanoma and viral peptides by the IFN-gamma-ELISPOT assay. Int J Cancer 93:549-555
11. Hadden JW (1999) The immunology and immunotherapy of breast cancer: an update. Int J Immunopharmacol 21:79-101
12. Hilders CG, Munoz IM, Nooyen Y, Fleuren GJ (1995) Altered HLA expression by metastatic cervical carcinoma cells as a factor in impaired immune surveillance. Gynecol Oncol 57:366-375
13. Hiraki A, Ikeda K, Yoshino T, Kaneshige T, Kiura K, Kunisada T, Fujiwara K, Tanimoto M, Harada M (2001) Tumor-specific cytotoxic T lymphocyte responses against chondrosarcoma with HLA haplotype loss restricted by the remaining HLA class I allele. Biochem Biophys Res Commun 286:786-791
14. Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, de Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6:199-208
15. Johnson SK, Kerr KM, Chapman AD, Kennedy MM, King G, Cockburn JS, Jeffrey RR (2000) Immune cell infiltrates and prognosis in primary carcinoma of the lung. Lung Cancer 27:27-35
16. Kataoka T, Shinohara N, Takayama H, Takaku K, Kondo S, Yonehara S, Nagai K (1996) Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. J Immunol 156:3678-3686
17. Kloor M, Becker C, Benner A, Woerner SM, Gebert J, Ferrone S, von Knebel DM (2005) Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Res 65:6418-6424
18. Kondratiev S, Sabo E, Yakirevich E, Lavie O, Resnick MB (2004) Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin Cancer Res 10:4450-4456
19. Lee SH, Shin MS, Park WS, Kim SY, Kim HS, Han JY, Park GS, Dong SM, Pi JH, Kim CS, Kim SH, Lee JY, Yoo NJ (1999) Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene 18:3754-3760
20. Leers MP, Kolgen W, Bjorklund V, Bergman T, Tribbick G, Persson B, Bjorklund P, Ramaekers FC, Bjorklund B, Nap M, Jornvall H, Schutte B (1999) Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 187:567-572
21. Menon AG, Janssen-van Rhijn CM, Morreau H, Putter H, Tollenaar RA, van de Velde CJ, Fleuren GJ, Kuppen PJ (2004) Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest 84:493-501
22. Menon AG, Morreau H, Tollenaar RA, Alphenaar E, Van Puijenbroek M, Putter H, Janssen-van Rhijn CM, van de Velde CJ, Fleuren GJ, Kuppen PJ (2002) Down-regulation of HLA-A expression correlates with a better prognosis in colorectal cancer patients. Lab Invest 82:1725-1733
23. Muris JJ, Meijer CJ, Cillessen SA, Vos W, Kummer JA, Bladergroen BA, Bogman MJ, MacKenzie MA, Jiwa NM, Siegenbeek van Heukelom LH, Ossenkoppele GJ, Oudejans JJ (2004) Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas. Leukemia 18:589-596
24. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139:271-279
25. Parham P, Barnstable CJ, Bodmer WF (1979) Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens. J Immunol 123:342-349
26. Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F (2003) Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol 171:1918-1926
27. Piras F, Colombari R, Minerba L, Murtas D, Floris C, Maxia C, Corbu A, Perra MT, Sirigu P (2005) The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer 104:1246-1254
28. Rajendra S, Ackroyd R, Karim N, Mohan C, Ho JJ, Kutty KM (2006) Loss of HLA class I and gain of class II expression are early events in carcinogenesis - clues from a study of Barrett's oesophagus. J Clin Pathol (in press)
29. Ramnath N, Tan D, Li Q, Hylander BL, Bogner P, Ryes L, Ferrone S (2006) Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival? Cancer Immunol Immunother 55:891-899
30. Rebai N, Malissen B (1983) Structural and genetic analyses of HLA class I molecules using monoclonal xenoantibodies. Tissue Antigens 22:107-117
31. Redondo M, Concha A, Oldiviela R, Cueto A, Gonzalez A, Garrido F, Ruiz-Cabello F (1991) Expression of HLA class I and II antigens in bronchogenic carcinomas: its relationship to cellular DNA content and clinical-pathological parameters. Cancer Res 51:4948-4954
32. Riemann D, Wenzel K, Schulz T, Hofmann S, Neef H, Lautenschlager C, Langner J (1997) Phenotypic analysis of T lymphocytes isolated from non-small-cell lung cancer. Int Arch Allergy Immunol 114:38-45
33. Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC (1997) The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 16:6914-6925
34. Sandel MH, Speetjens FM, Menon AG, Albertsson PA, Basse PH, Hokland M, Nagelkerke JF, Tollenaar RA, van de Velde CJ, Kuppen PJ (2005) Natural killer cells infiltrating colorectal cancer and MHC class I expression. Mol Immunol 42:541-546
35. +) T cell infiltrations within esophageal carcinomas. Cancer Res 61:3932-3936
36. Seliger B (2005) Strategies of tumor immune evasion. Bio-Drugs 19:347-354
37. Sernee MF, Ploegh HL, Schust DJ (1998) Why certain antibodies cross-react with HLA-A and HLA-G: epitope mapping of two common MHC class I reagents. Mol Immunol 35:177-188
38. Stam NJ, Spits H, Ploegh HL (1986) Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 137:2299-2306
39. Sy SM, Wong N, Lee TW, Tse G, Mok TS, Fan B, Pang E, Johnson PJ, Yim A (2004) Distinct patterns of genetic alterations in adenocarcinoma and squamous cell carcinoma of the lung. Eur J Cancer 40:1082-1094
40. Toomey D, Smyth G, Condron C, Kelly J, Byrne AM, Kay E, Conroy RM, Broe P, Bouchier-Hayes D (2003) Infiltrating immune cells, but not tumour cells, express FasL in non-small cell lung cancer: no association with prognosis identified in 3-year follow-up. Int J Cancer 103:408-412
41. Treilleux I, Blay JY, Bendriss-Vermare N, Ray-Coquard I, Bachelot T, Guastalla JP, Bremond A, Goddard S, Pin JJ, Barthelemy-Dubois C, Lebecque S (2004) Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 10:7466-7474
42. van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R (1988) Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319:1239-1245
43. Verdegaal EM, Huinink DB, Hoogstraten C, Marijnissen AK, Gorsira MB, Claas FH, Osanto S (1999) Isolation of broadly reactive, tumor-specific, HLA Class-I restricted CTL from blood lymphocytes of a breast cancer patient. Hum Immunol 60:1195-1206
44. Verduyn W, Doxiadis II, Anholts J, Drabbels JJ, Naipal A, D'Amaro J, Persijn GG, Giphart MJ, Schreuder GM (1993) Biotinylated DRB sequence-specific oligonucleotides. Comparison to serologic HLA-DR typing of organ donors in eurotransplant. Hum Immunol 37:59-67
45. Wiegant J, Bezrookove V, Rosenberg C, Tanke HJ, Raap AK, Zhang H, Bittner M, Trent JM, Meltzer P (2000) Differentially painting human chromosome arms with combined binary ratio-labeling fluorescence in situ hybridization. Genome Res 10:861-865
46. Yang SY, Morishima Y, Collins NH, Alton T, Pollack MS, Yunis EJ, Dupont B (1984) Comparison of one-dimensional IEF patterns for serologically detectable HLA-A and B allotypes. Immunogenetics 19:217-231
47. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348:203-213